Curing diffuse large B-cell lymphomas in elderly patients.
In older patients lymphoma is a frequent disease and diffuse large B-cell lymphoma (DLBCL) represents >60% of all lymphomas. Elderly patients with DLBCL are a heterogeneous population and the definition of elderly varies within the literature. Even though the combination of rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) is considered standard therapy for DLBCL, management of elderly patients remains challenging. Accurate selection of patients able to tolerate proper immune-chemotherapy is crucial and the comprehensive geriatric assessment based on age, comorbidities and functional abilities of daily living, may help to discriminate among fit, unfit or frail patients. Unfit and frail patients need to be treated with chemotherapy at reduced intensity. Novel compounds with a favorable toxicity profile may represent a promising first-line therapeutic option in combination with standard immune-chemotherapy or as single agent in the relapse/refractory setting.